Hopefully this will not be relevant to you, but if you have HCC here is a slide set from Clinical Care Options that outlines the latest advances.

Interestingly Incepta in Bangladesh have a range of generic anti cancer agents. As of a week ago….

Nivolumab has not been launched yet but we have launched Erlotinib, Gefitinib and Osimertinib in addition to Adalimumab, Denosumab and Rituximab.

While there is not a magic bullet(s) (as yet) it would be possible to used combined therapy with generics that are cost prohibitive otherwise.